Trials / NCT00458575
A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa
Terminated Phase 1 Gene therapy
Why it stopped: Internal Business Decision
- Sponsor
- Centocor, Inc.
- Treatment
- CNTO 2476
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 7 participants
- Started
- 2007-04
- Main results expected
- 2013-08
- Results posted
- Not yet
- Record last updated
- 2014-06-26
What the study is testing
The main purpose of this study is to evaluate the preliminary safety and immunogenicity (ability of an antigen to provoke immune response in the human body) of CNTO 2476, administered subretinally, in participants with advanced retinitis pigmentosa (RP; disease of the eye that leads to loss of vision and blindness) with either light perception only (LP) or hand motion (HM).
Where it runs
United States (3)
- , Miami, Florida
- , Southwest Portland, Oregon
- , Dallas, Texas